Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death. (10th June 2020)

• Record Type: Journal Article
• Authors: Mirza, Kazim; Landoski, Kathryn; Thakar, Dilip; Heir-Singh, Jagtar; Jackson, Timothy; Kassab, Cynthia
• Other Names: Tan Benjamin Academic Editor.
• Is Part Of: Case reports in anesthesiology. Volume 2020(2020)
• Publication Date: 2020-06-10
• Subjects: Anesthesiology -- Periodicals; 617.9605
• DOI: 10.1155/2020/8767195
• Languages: English
• ISSNs: 2090-6382

Abstract

Abstract : On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. It is a first and unique selective nondepolarizing steroidal muscle relaxant (NDSMR) binding agent with a great affinity for rocuronium and vecuronium. However, there have been several recently published case reports of bradycardia and asystole immediately after sugammadex administration for the reversal. This report presents a case of sugammadex administration followed by rapidly progressing bradycardia leading to asystole and subsequent death. The family has provided the written consent to share this case report.